We read the article, entitled "Assessment of serum hepcidin levels in patients with non-ST elevation myocardial infarction," by Altun et al. (1) published in Anatolian J Cardiol 2014; 14: 515-8. Serum hepcidin levels were comparable among NSTEMI patients and control subjects. Also, its concentration did not change 6 hours after admission. The authors concluded that hepcidin could not be used as a marker of myocardial necrosis in NSTEMI patients. We thank the authors for drawing attention to a very important and challenging field of cardiology: markers in acute coronary syndromes. However, in their study, we think that there are some important questions that need to be answered.
